bg

LEADING THE DEVELOPMENT OF NEW VASCULAR THERAPEUTICS

LEARN MORE

Technology

Utilizing a proprietary research platform, this technology is addressing the need for a new class of drugs to treat various vascular diseases. Our lead indication is for a First-In-Class therapeutic eye drop for the treatment of Primary Open Angle Glaucoma.

Learn More

Research

We are developing a unique molecule in the form of an easy to administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of intra-ocular eye pressure (IOP), one of the main causes of Glaucoma. We are the only company targeting this method of action.

Learn More

Pipeline

A deep pipeline of novel therapeutics can be developed from this research platform, which would treat a spectrum of vascular diseases including Cystic Kidney Disease, Pediatric Glaucoma, and Inflammation.

Learn More

BG2

ABOUT US

Mannin Research is a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases. Our lead indication is for treatment of Primary Open-Angle Glaucoma.

MEET THE TEAM

GEORGE N. NIKOPOULOS

Chief Executive Officer & President

Dr. Nikopoulos has worked with and advised a number of biotechnology, pharmaceutical and med-tech companies.
Read More

SUSAN E. QUAGGIN

Chief Scientific
Officer

Dr. Quaggin is the director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension.
Read More

CHRISTOPHER A. SMITH

Chairman, Board of Directors

Chris is a successful and dynamic entrepreneur, with a wide range of experience with the initial execution of business concepts.
Read More

GEOFFREY D. SMITH

Secretary, Board of Directors

Geoffrey specializes in supporting and building small companies and has extensive experience as a seasoned entrepreneur with over 20 companies.
Read More